What are the lastest treaments for mHSPC

According to the most recent NCCN Guidelines for Prostate Cancer, there are several approved treatment options for mHSPC:

1. Combination Therapy Options:

• ADT (Androgen Deprivation Therapy) plus one of the following: • Abiraterone acetate + prednisone • Enzalutamide • Darolutamide • Apalutamide • Docetaxel chemotherapy

The American Society of Clinical Oncology (ASCO) Guidelines specifically recommend that:

• Most patients should receive ADT plus one of the novel hormonal agents (abiraterone, enzalutamide, darolutamide, or apalutamide)
• The choice between agents should be based on: • Side effect profiles • Drug interactions • Patient preferences • Cost considerations

According to the National Cancer Institute (NCI), recent clinical trials have shown that these combination approaches significantly improve:

• Overall survival
• Time to disease progression
• Quality of life outcomes

Important notes:

1. Treatment selection should be individualized based on your specific situation
2. Factors like disease volume, prior treatments, and overall health status influence treatment choices
3. Always discuss these options with your oncologist to determine the best approach for your specific case

I recommend discussing these treatment options with your healthcare team, as they can best determine which approach is most appropriate for your individual situation.